Global Gene Therapy Partnering Terms and Agreements 2010 to 2017

Publisher Name :
Date: 01-Apr-2017
No. of pages: 231
Inquire Before Buying

Summary

The Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides comprehensive understanding and unprecedented access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Gene Therapy Partnering Agreements 2010-2017 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in gene therapy partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Gene therapypartnering contract documents

Top gene therapy deals by value

The Global Gene Therapy Partnering Terms and Agreements 2010-2017 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2010 including financial terms where available including over 500 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What are the precise rights granted or optioned?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of Gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Gene therapy dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Gene therapy deals since 2010. Deals are listed by headline value, signed by big pharma, most active Gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Gene therapy dealmaking with a brief summary followed by a comprehensive listing of Gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Gene therapy technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gene therapy technologies and products.

Report scope

Global Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.

Global Gene Therapy Partnering Terms and Agreements includes:

Trends in gene therapy dealmaking in the biopharma industry since 2010

Analysis of gene therapy deal structure

Access to headline, upfront, milestone and royalty data

Case studies of real-life gene therapy deals

Access to over 200 gene therapy deals

The leading gene therapy deals by value since 2010

Most active gene therapy dealmakers since 2010

The leading gene therapy partnering resources

In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Gene Therapy Partnering Terms and Agreements provides the reader with the following key benefits:

In-depth understanding of gene therapy deal trends since 2010

Access to headline, upfront, milestone and royalty data

Analysis of the structure of gene therapy agreements with numerous real life case studies

Comprehensive access to 200 actual gene therapy deals entered into by the world's biopharma companies, together with real world clause examples

Full listing of gene therapy deals by company A-Z, deal value, phase of development, deal type, and therapy focus

Identify leading gene therapy deals by value since 2010

Identify the most active gene therapy dealmakers since 2010

Detailed access to actual gene therapy contracts enter into by the leading fifty bigpharma

Insight into the terms included in gene therapy agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Gene Therapy Partnering Terms and Agreements 2010 to 2017

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking

2.1. Introduction
2.2. Gene therapy partnering over the years
2.3. Most active Gene therapy dealmakers
2.4. Gene therapy partnering by deal type
2.5. Gene therapy partnering by therapy area
2.6. Deal terms for Gene therapy partnering
2.6.1 Gene therapy partnering headline values
2.6.2 Gene therapy deal upfront payments
2.6.3 Gene therapy deal milestone payments
2.6.4 Gene therapy royalty rates

Chapter 3 - Leading Gene therapy deals

3.1. Introduction
3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers

4.1. Introduction
4.2. Most active Gene therapy dealmakers
4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory

5.1. Introduction
5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking

Appendices

Appendix 1 - Gene therapy deals by company A-Z

Appendix 2 - Gene therapy deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Gene therapy deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Research
Spin out
Sub-license
Supply
Technology transfer

Appendix 4 - Gene therapy deals by therapy area

Cardiovascular
Central Nervous System
Genetic disorders
Hematology
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Respiratory

Appendix 5 -Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Gene therapy partnering since 2010
Figure 2: Active Gene therapy dealmaking activity since 2010
Figure 3: Gene therapy partnering by deal type since 2010
Figure 4: Gene therapy partnering by disease type since 2010
Figure 5: Gene therapy deals with a headline value
Figure 6: Gene therapy deals with an upfront value
Figure 7: Gene therapy deals with a milestone value
Figure 8: Gene therapy deals with a royalty rate value
Figure 9: Top Gene therapy deals by value since 2010
Figure 10: Most active Gene therapy dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • 2017 Top 5 Animal Genetics Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Apr-2017        Price: US 4960 Onwards        Pages: 123
    "This report will be delivered in 2-3 business days after the order is placed." This report studies Animal Genetics in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Animal Genetics Players in each region, with sales, price, revenue and market share for top 5 manufacturer, covering - Genus PLC - Hendrix Genetics - EW Group GmbH - Zoetis - CRV Holding......
  • 2017-2022 China Animal Genetics Market Report (Status and Outlook)
    Published: 12-Apr-2017        Price: US 3360 Onwards        Pages: 115
    "This report will be delivered in 2-3 business days after the order is placed." The Animal Genetics market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In China market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Genus PLC - Hendrix Genetics - EW......
  • 2017-2022 Germany Animal Genetics Market Report (Status and Outlook)
    Published: 12-Apr-2017        Price: US 3360 Onwards        Pages: 115
    "This report will be delivered in 2-3 business days after the order is placed." The Animal Genetics market size will be XX million (USD) in 2022 in Germany, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Germany market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Genus PLC - Hendrix Genetics ......
  • 2017-2022 Global Top Countries Animal Genetics Market Report
    Published: 12-Apr-2017        Price: US 4960 Onwards        Pages: 123
    "This report will be delivered in 2-3 business days after the order is placed." This report studies Animal Genetics in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Middle East and Africa, focuses on the top Manufacturers in each country, covering - Genus PLC - Hendrix Genetics - EW Group GmbH - Zoetis - CRV Hol......
  • 2017-2022 India Animal Genetics Market Report (Status and Outlook)
    Published: 12-Apr-2017        Price: US 3360 Onwards        Pages: 115
    "This report will be delivered in 2-3 business days after the order is placed." The Animal Genetics market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In India market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Genus PLC - Hendrix Genetics - EW......
  • 2017-2022 Japan Animal Genetics Market Report (Status and Outlook)
    Published: 12-Apr-2017        Price: US 3360 Onwards        Pages: 115
    "This report will be delivered in 2-3 business days after the order is placed." The Animal Genetics market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In Japan market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Genus PLC - Hendrix Genetics - EW......
  • 2017-2022 UK Animal Genetics Market Report (Status and Outlook)
    Published: 12-Apr-2017        Price: US 3360 Onwards        Pages: 115
    "This report will be delivered in 2-3 business days after the order is placed." The Animal Genetics market size will be XX million (USD) in 2022 in UK, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In UK market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Genus PLC - Hendrix Genetics - EW Group......
  • 2017-2022 United States Animal Genetics Market Report (Status and Outlook)
    Published: 12-Apr-2017        Price: US 3360 Onwards        Pages: 115
    "This report will be delivered in 2-3 business days after the order is placed." The Animal Genetics market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022. In United States market, the top players include many company. With key sales data like sales (volume), revenue, market share for top players.such as - Genus PLC - Hendrix Gene......
  • United States Gene Therapy Market Report 2017
    Published: 04-Jan-2017        Price: US 3800 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Gene Therapy Revenue, means the sales value of Gene Therapy This report studies sales (consumption) of Gene Therapy in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bluebird Bio - Sangamo - Spark Therapeutics - Dimension Therapeutics - Avalanche Bio - Celladon - Vical Inc. - Advantagene ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs